Pharmaceutical Industry Information Portal

Sanofi is gaining momentum by teaming up with McLaren Racing and launching Foundation S

Sanofi announces that it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of the company’s ambition to attain world-class standards of manufacturing excellence.

McLaren Racing experts will collaborate with Sanofi’s Industrial Affairs team to enable continued optimization of its manufacturing operations, enabling its global network to better support the supply of its broad portfolio, as well as enhancing the delivery of its R&D pipeline, with 25 new launches expected in the next five years to meet patients’ needs around the world.

Zak Brown, Chief Executive Officer, McLaren Racing, said:

We are thrilled to be partnering with Sanofi. It is important that two global companies who share values work together to maximise performance. We look forward to continuing to collaborate with Sanofi to make a positive impact not only in manufacturing but to help Sanofi improve patients’ lives.

Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance. The partnership will bring a race-like mindset, emulating the competitive, fast paced environment of F1 racing to help accelerate improvements, learnings and sharing of best practices individually and collectively across sites, fostering a “one Sanofi spirit.” This unique opportunity will marry the best of the two companies with the speed, agility, teamwork, and constant improvement required to succeed in motor racing, as well as in healthcare discoveries.

The company also launched today Foundation S – The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partnerships and collective action, Foundation S will focus on three critical areas: childhood cancer, the health of communities most vulnerable to the effects of climate change and pollution, and access to lifesaving medicines and vaccines.

Serge Weinberg, Chairman of the Board of Directors, Sanofi and President, Foundation S, said:

As a global healthcare company, we must take part in tackling some of the challenges our society faces. We are proud of what the Sanofi Espoir Foundation has achieved this past decade and the legacy it leaves. The world changes at an incredible pace and numerous new systemic challenges emerge. Now is the right time to go one step further and Foundation S is the right structure, more focused, more agile, to better help vulnerable populations across the world.

This endowment fund allows Foundation S to open the opportunity for co-sponsorship of public initiatives and broader partnerships. Through its direct product donation programs and humanitarian efforts, and by working with partners and organizations around the world, Foundation S further strengthens Sanofi’s longstanding commitment to society.


Expert Articles